Publications by authors named "Edward M Connor"

Claim this Profile
I
I-ACT for Children: helping close the gap in drug approval for adults and children.
Max J Coppes, Cindy Jackson, Edward M Connor

Pediatr Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ensuring continued progress for development of COVID-19 therapeutics in children.
Gary J Noel, Roberta L DeBiasi, Wallace Crandall, Edward M Connor

Pediatr Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.
Blythe C Dillingham, Susan M Knoblach, Gina M Many, Brennan T Harmon, Amanda M Mullen, Edward M Connor

Cell Mol Neurobiol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sponsors meet scientists to speed pediatric medicines development.
Jonathan M Davis, William E Smoyer, Edward M Connor, W Charles Huskins, Cindy Pastern

Sci Transl Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting the demand for pediatric clinical trials.
Edward M Connor, William E Smoyer, Jonathan M Davis, Anne Zajicek, Linda Ulrich

Sci Transl Med· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies.
Eric P Hoffman, Edward M Connor

Discov Med· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
Christopher R Heier, Jesse M Damsker, Qing Yu, Blythe C Dillingham, Tony Huynh, Edward M Connor

EMBO Mol Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Eric P Hoffman, Erica Reeves, Jesse Damsker, Kanneboyina Nagaraju, John M McCall, Edward M Connor

Phys Med Rehabil Clin N Am· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The need for rigorous evidence on medication use in preterm infants: is it time for a neonatal rule?
Jonathan M Davis, Edward M Connor, Alastair J J Wood

JAMA· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
Eric P Hoffman, Abby Bronson, Arthur A Levin, Shin'ichi Takeda, Toshifumi Yokota, Edward M Connor

Am J Pathol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
Xavier Carbonell-Estrany, Eric A F Simões, Ron Dagan, Caroline B Hall, Brian Harris, Edward M Connor

Pediatrics· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Rosanna Lagos, John P DeVincenzo, Alma Muñoz, Micki Hultquist, Joann Suzich, Edward M Connor

Pediatr Infect Dis J· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
Katia Abarca, Elizabeth Jung, Pilar Fernández, Liang Zhao, Brian Harris, Edward M Connor

Pediatr Infect Dis J· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of protection provided by live attenuated influenza vaccine in children.
Christopher S Ambrose, Tingting Yi, Robert E Walker, Edward M Connor

Pediatr Infect Dis J· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live attenuated versus inactivated influenza vaccine in infants and young children.
Robert B Belshe, Kathryn M Edwards, Timo Vesikari, Steven V Black, Robert E Walker, Edward M Connor

N Engl J Med· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Live attenuated influenza vaccine in children.
Christopher S Ambrose, Robert E Walker, Edward M Connor

Semin Pediatr Infect Dis· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.
Xavier Sáez-Llorens, María T Moreno, Octavio Ramilo, Pablo J Sánchez, Franklin H Top, Edward M Connor

Pediatr Infect Dis J· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
Timothy F Feltes, Allison K Cabalka, H Cody Meissner, Franco M Piazza, David A Carlin, Edward M Connor

J Pediatr· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis